[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371785-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-371785-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","braf-v600e-mutation-has-variable-tumor-specific-effects-on-expression-of-mapk-pathway-genes-that-could-affect-patient-outcome","BRAF V600E Mutation Has Variable Tumor-Specific Effects on Expression of MAPK Pathway Genes That Could Affect Patient Outcome","","BRAF inhibitors achieve a 50–70% response rate in melanoma but show reduced effectiveness in thyroid cancer. Differential response is investigated through how downstream mitogen-activated protein kinase (MAPK) pathway genes are activated and expressed. A retrospective comparison uses whole exome and transcriptome sequencing of melanoma and thyroid tumors from April 2019 to October 2023, together with tumor registry outcome data. BRAF V600E associates with higher MAPK gene expression in melanoma, while thyroid cancer shows no such increase or activation and no overall survival difference. Results suggest cancer-type–specific MAPK pathway effects may contribute to differing responses.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/braf-v600e-mutation-has-variable-tumor-specific-effects-on-expression-of-mapk-pathway-genes-that-could-affect-patient-outcome/371785/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/braf-v600e-mutation-has-variable-tumor-specific-effects-on-expression-of-mapk-pathway-genes-that-could-affect-patient-outcome/371785.png","ImageObject",300,407,{"name":42,"@type":43},"Mimi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"Why might BRAF inhibitors work better in melanoma than thyroid cancer?","Question",{"text":63,"@type":64},"The study links differential response to differences in expression and activation of downstream MAPK pathway genes driven by BRAF V600E. Melanoma shows increased MAPK gene expression, while thyroid cancer does not.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What methods were used to analyze tumor genomic and expression features?",{"text":68,"@type":64},"The analysis compares whole exome and transcriptome sequencing across melanoma and thyroid cancers collected from April 2019 to October 2023. A MAPK Activation Score (MPAS) was calculated from Z-score normalized, log-transformed expression across 10 MAPK-associated genes.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main findings on BRAF V600E expression and MAPK pathway activation?",{"text":72,"@type":64},"In melanoma, BRAF V600E is associated with increased expression of BRAF and MAPK-associated genes versus wild-type BRAF. In thyroid cancer, BRAF V600E is not associated with increased expression or MAPK pathway activation.",{"name":74,"@type":61,"acceptedAnswer":75},"Did BRAF mutation status affect overall survival?",{"text":76,"@type":64},"No significant difference in overall survival was observed in the subset of patients with available outcome data based on BRAF mutation status.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},371785,1790904709,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,109,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},"Technology",50,"technology",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},7,"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},2336477974920,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \nBRAF V600E Mutation Has Variable Tumor-Specific Effects on Expression of MAPK Pathway Genes That Could Affect Patient Outcome  \nSourat Darabi 1, *, Phillip Stafford 1,2,3, David R. Braxton 1, Carlos E. Zuazo 1, Taylor J. Brodie 1 and Michael J. Demeure 1,4  \nAcademic Editor: Malgorzata Gabriela Wasniewska  \nReceived: 19 June 2025  \nRevised: 7 August 2025  \nAccepted: 13 August 2025  \nPublished: 16 August 2025  \nCitation: Darabi, S.; Stafford, P.; Braxton, D.R.; Zuazo, C.E.; Brodie, T.J.; Demeure, M.J. BRAFV600E Mutation Has Variable Tumor-Specific Effects on Expression of MAPK Pathway Genes That Could Affect Patient Outcome. Int. J. Mol. Sci. 2025, 26, 7910 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms26167910  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Hoag Family Cancer Institute, Newport Beach, CA 92663, USA; [phillip.stafford@asu.edu](phillip.stafford@asu.edu) (P.S.); [david.braxton@hoag.org](david.braxton@hoag.org) (D.R.B.); [taylor.brodie@hoag.org](taylor.brodie@hoag.org) (T.J.B.); [michael.demeure@hoag.org](michael.demeure@hoag.org) (M.J.D.)  \n2 School of Life Sciences, Arizona State University, Tempe, AZ 85287, USA  \n3 Fulgent Genetics, El Monte, CA 91731, USA  \n4 Translational Genomics Research Institute, Phoenix, AZ 85004, USA  \n* Correspondence: [sourat.darabi@hoag.org](sourat.darabi@hoag.org)  \nAbstract  \nBRAF inhibitors have a 50–70% response rate in melanoma but are less effective for thyroid cancer. Differential response may be from activation or expression of downstream mitogen-activated protein kinase (MAPK) pathway genes. Retrospective analysis compared whole exome and transcriptome sequencing in melanoma and thyroid cancers from April 2019 to October 2023 . The MAPK Activation Score (MPAS) was calculated using Z-score normalized/log-transformed values indicating expression across 10 MAPK-associated genes. Our tumor registry provided outcome data. BRAF V600E mutations were identified in 33 of 200 (17%) melanomas and 14 (7%) had other BRAF mutations (V600K/R) . Of 49 thyroid tumor samples, BRAF V600E mutations were found in 19 (39%) . RNA expression of BRAF and the 10 MAPK-associated genes were increased in melanomas with V600E compared to wild-type BRAF (p = 0.02) . Conversely, BRAF V600E mutation in thyroid cancer was not associated with increased expression nor MAPK pathway activation. No significant difference in overall survival based on BRAF mutation was observed in the subset of patients where data was available. The MAPK pathway is differentially affected by the different cancers, with increased MAPK activation observed in melanoma and not in thyroid cancer. This may account in part for the observed differential response to BRAF inhibitors.  \nKeywords: BRAF mutations; RNA expression; whole exome sequencing; whole transcriptome sequencing; thyroid cancer; melanoma  \n1. Introduction  \nGenomic databases offer an opportunity for investigators to study biologically interesting questions. The insights garnered may be more powerful when the genomic data is annotated with patient clinical data and outcomes of treatment. The cBioPortal for Cancer Genomics is an open-access, open-source resource that provides visualization, interrogation, analysis, and download of large-scale cancer genomics data sets [1,2] . To this end, our hospital has developed its own instance of cBioPortal to archive its genomic data from several clinical commercial labs, and we are in the process of integrating this data with our tumor registry database. To date, our cancer center has collected genomic data from nearly  \n6000 independent patient tumors. The biologically relevant question we addr","cbCaiiWvwFcDuP4a","https://ap.wps.com/l/cbCaiiWvwFcDuP4a","pdf",2275828,14,"English","# Abstract\n# 1. Introduction\n# 2. Results","[{\"question\":\"Why might BRAF inhibitors work better in melanoma than thyroid cancer?\",\"answer\":\"The study links differential response to differences in expression and activation of downstream MAPK pathway genes driven by BRAF V600E. Melanoma shows increased MAPK gene expression, while thyroid cancer does not.\"},{\"question\":\"What methods were used to analyze tumor genomic and expression features?\",\"answer\":\"The analysis compares whole exome and transcriptome sequencing across melanoma and thyroid cancers collected from April 2019 to October 2023. A MAPK Activation Score (MPAS) was calculated from Z-score normalized, log-transformed expression across 10 MAPK-associated genes.\"},{\"question\":\"What were the main findings on BRAF V600E expression and MAPK pathway activation?\",\"answer\":\"In melanoma, BRAF V600E is associated with increased expression of BRAF and MAPK-associated genes versus wild-type BRAF. In thyroid cancer, BRAF V600E is not associated with increased expression or MAPK pathway activation.\"},{\"question\":\"Did BRAF mutation status affect overall survival?\",\"answer\":\"No significant difference in overall survival was observed in the subset of patients with available outcome data based on BRAF mutation status.\"}]","BRAF V600E Mutation Has Variable Tumor-Specific Effects on Expression of MAPK Pathway Genes That Could Affect Patient Outcome | PDF",1790192857,35,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e935c29fd1cad591f542d6b82e6b56f.webp",983,1390,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c7cade07a85a7215c99398909caf97c.webp",982,1388,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e3c42c42de8d29c9fffbd70b9438a1c.webp",981,1387,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea7bd19230bb047146757c5d261cc960.webp",980,1385]